Repatha Cost in Iowa 2026: Prices, Medicaid, Insurance, and Compounded Options

What Does Repatha Actually Cost in Iowa?

Evolocumab (brand name Repatha) carries an Amgen wholesale acquisition cost of approximately $580 per month in 2026 for the 140 mg auto-injector used on a twice-monthly schedule. The 420 mg monthly-dosing SureClick cartridge lists at a similar price. Cash-pay prices at Iowa retail pharmacies mirror that figure closely. Patients without insurance or without an active manufacturer coupon are unlikely to pay less than $550 to $590 per fill at chains such as Hy-Vee Pharmacy, Walgreens, or CVS locations across Des Moines, Cedar Rapids, and Davenport.

The wholesale acquisition cost figure is not the price Amgen receives from large insurers. Pharmacy benefit managers negotiate rebates, which is why your insurer may pay far less per claim than $580, but those savings do not pass directly to cash-pay patients. For anyone without coverage, the list price is the effective price unless a discount program applies. The FDA-approved Repatha prescribing information confirms dosing and formulations.

PCSK9 inhibitors as a class were first approved in 2015. By 2017, the FOURIER trial (N=27,564 patients with established atherosclerotic cardiovascular disease, or ASCVD) demonstrated that adding evolocumab to statin therapy cut LDL-C by a median of 59% and reduced the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, unstable angina, or coronary revascularization by 15% relative to placebo over a median 2.2 years of follow-up. FOURIER, NEJM 2017.

That efficacy evidence is strong. Price barriers, particularly in states like Iowa where Medicaid coverage is absent, remain the primary obstacle to access.

Does Iowa Medicaid Cover Repatha?

Iowa Medicaid does not cover Repatha for most enrollees as of mid-2025, and that status has carried into 2026. The Iowa Department of Health and Human Services pharmacy benefit lists evolocumab as non-covered under the standard fee-for-service formulary. Iowa Medicaid managed care plans (AmeriHealth Caritas Iowa, Molina Healthcare of Iowa, and UnitedHealthcare Community Plan of Iowa) each maintain their own formularies, and none currently list evolocumab as a covered benefit at any tier without a successful exceptions process. The CDC notes that ASCVD is the leading cause of death in Iowa, affecting 35% of adult Iowans at elevated cardiovascular risk.

An exceptions or prior authorization request to Iowa Medicaid for Repatha is possible in theory but rarely approved. The state program cites the availability of high-intensity statin therapy and ezetimibe as preferred alternatives. Patients who have documented statin intolerance or who carry a confirmed diagnosis of heterozygous familial hypercholesterolemia (HeFH) may have marginally better odds, but approval is not guaranteed. ACC/AHA 2022 cholesterol guidelines recommend PCSK9 inhibitors for very high-risk ASCVD patients with LDL-C persistently above 70 mg/dL on maximally tolerated statin plus ezetimibe.

Dual-eligible Medicare/Medicaid patients in Iowa should check their Medicare Part D plan separately. Repatha does appear on select Part D formularies, usually at Tier 4 or Tier 5, with step-therapy requirements.

Which Iowa Commercial Insurance Plans Cover Repatha?

Most major Iowa commercial insurers place evolocumab on a specialty tier with a prior authorization requirement and, frequently, a mandatory step-therapy sequence. Plans active in Iowa's ACA marketplace and employer markets include those administered by Wellmark Blue Cross Blue Shield of Iowa, Medica, and UnitedHealthcare. Each requires documented evidence of:

1. LDL-C at or above a specified threshold (often 70 mg/dL for ASCVD, or 100 mg/dL for HeFH) despite maximally tolerated statin therapy.
2. A trial of ezetimibe for at least 90 days.
3. A confirmed diagnosis of HeFH by genetic testing or clinical criteria, or established ASCVD with a high-risk designation.

The prior authorization process typically takes 3 to 14 business days. Denial rates for initial submissions are high across all payers. A 2021 analysis published in JAMA Cardiology found that PCSK9 inhibitor prior authorization requests were denied in roughly 80% of initial submissions, though appeal success rates improved with complete documentation. JAMA Cardiology, 2021.

Your prescribing physician or a HealthRX-affiliated clinician can prepare a strong prior auth package. The letter should include the patient's LDL-C history, documentation of statin trials (including any adverse effects), the clinical indication (HeFH or very-high-risk ASCVD), and explicit reference to the ACC/AHA 2022 guideline recommendation. ACC/AHA 2022 guideline on PCSK9 inhibitors.

How the Amgen Repatha Savings Card Works in Iowa

Amgen offers a copay assistance program for commercially insured, non-government-insured patients. Under the current program terms, eligible Iowa patients pay as little as $0 per month, with Amgen covering up to $3,600 per calendar year in copay costs. Patients enrolled in Medicare, Medicaid, or any other federal or state insurance program are not eligible. Program details are maintained at the Amgen patient assistance page; eligibility is confirmed through the prescribing pharmacy at point of sale.

The savings card auto-applies at most Iowa retail pharmacies. After the $3,600 annual cap is reached, patients pay the plan's full specialty cost-share, which can exceed $200 per fill on high-deductible plans. Patients approaching that cap should contact Amgen's patient support line at least 30 days before their renewal fill to explore bridge options.

Patients without commercial insurance who cannot afford the list price may qualify for the Amgen Safety Net Foundation program, which provides Repatha at no cost to patients meeting income criteria (generally at or below 400% of the federal poverty level). Amgen Safety Net Foundation eligibility criteria.

Is Compounded Evolocumab Legal in Iowa?

Compounded evolocumab is legal in Iowa when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Iowa Board of Pharmacy rules permit 503A compounding facilities to prepare non-commercially available formulations, and evolocumab can meet that threshold when a prescriber documents a clinical rationale. FDA 503A compounding pharmacy regulations.

The regulatory boundary is important. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare individualized prescriptions. Section 503B governs outsourcing facilities that produce larger sterile batches. Evolocumab compounded under 503A is prepared as a sterile injectable on a per-prescription basis, which is legal but carries a different quality oversight framework than an FDA-approved biologic. FDA overview of 503A vs. 503B.

Cost is the primary driver of patient interest in compounded evolocumab. While prices vary by pharmacy and prescription volume, compounded versions are available at a fraction of the brand list price. Patients considering this route should verify:

• The pharmacy holds an active Iowa Board of Pharmacy license.
• The compounding pharmacist can document the source API and sterility testing.
• The prescribing clinician has documented the medical rationale on file.

Telehealth prescribers in Iowa can legally write prescriptions for compounded evolocumab to patients they have evaluated, provided the clinical documentation meets the standard of care. Iowa Board of Pharmacy licensing search.

Clinical Background: Why Evolocumab Is Prescribed

Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 normally degrades LDL receptors on hepatocyte surfaces. By blocking PCSK9, evolocumab preserves LDL receptor recycling and allows the liver to clear more LDL-C from circulation. Mechanism review, NLM.

The FOURIER trial (N=27,564) showed evolocumab 140 mg every 2 weeks reduced LDL-C from a median baseline of 92 mg/dL to 30 mg/dL, a 59% reduction. The primary composite MACE endpoint fell by 15% (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) at a median 2.2 years of follow-up. FOURIER, NEJM 2017.

The GLAGOV trial (N=968) further showed that evolocumab produced regression of coronary atherosclerosis as measured by intravascular ultrasound. Percent atheroma volume decreased by 0.95% in the evolocumab group versus a 0.05% increase in the placebo group (P<0.001). GLAGOV, JAMA 2016.

FDA-approved indications for evolocumab include:

• Adults with heterozygous familial hypercholesterolemia (HeFH)
• Adults with homozygous familial hypercholesterolemia (HoFH), at 420 mg monthly
• Adults with established ASCVD requiring additional LDL-C lowering

The American College of Cardiology's 2022 expert consensus decision pathway specifies that PCSK9 inhibitor therapy is appropriate in very-high-risk ASCVD patients with LDL-C above 70 mg/dL despite maximally tolerated statin plus ezetimibe, and in HeFH patients with LDL-C above 100 mg/dL on maximally tolerated statin. ACC 2022 PCSK9 pathway.

The American Heart Association's 2019 primary prevention guideline notes that PCSK9 inhibitors carry the strongest evidence base for secondary prevention. AHA 2019 primary prevention guideline.

Dosing and Administration in Iowa Telehealth Practice

Standard evolocumab dosing is 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly. The 420 mg monthly dose is given as three consecutive 140 mg injections within 30 minutes using the SureClick autoinjector or the single-use prefilled syringe. Both schedules produce equivalent LDL-C lowering in clinical trials. FDA prescribing information.

Injection sites include the abdomen, upper arm, or thigh. Patients self-administer after a brief training session. Iowa telehealth providers can conduct that training via video visit, satisfying the Iowa telehealth prescribing standard as long as a synchronous audio-video encounter is documented. Iowa Code Section 135.190 on telehealth services.

LDL-C should be checked 4 to 12 weeks after initiation and after any dose change. Most patients reach their LDL-C target within 4 to 8 weeks. NLM clinical pharmacology reference for evolocumab.

Comparing Cost Pathways for Iowa Patients

Access to evolocumab in Iowa runs through four distinct pathways, each with a different cost profile.

Brand Repatha, commercially insured with Amgen copay card. After successful prior authorization, eligible patients use the Amgen savings card to reduce their monthly out-of-pocket cost to near $0, up to the $3,600 annual cap. This is the most common successful pathway for employed Iowans with employer-sponsored insurance. Amgen Repatha patient support.

Brand Repatha, Part D Medicare. Tier 4 or Tier 5 placement typically means 25% to 33% coinsurance in the initial coverage phase, with costs falling after the catastrophic coverage threshold is met. The 2024 Inflation Reduction Act Medicare reforms cap out-of-pocket Part D spending at $2,000 per year starting in 2025, which reduces the annual exposure for Medicare patients on specialty drugs. CMS Medicare Part D 2025 reforms.

Brand Repatha, uninsured cash pay. At $580 per month with no coupon, annual cost exceeds $6,900. This is not sustainable for most Iowa households. GoodRx and similar discount platforms rarely reduce the price below $520 to $550 per month for the brand. Patients in this situation should prioritize either the Amgen Safety Net Foundation or a compounded alternative. GoodRx evolocumab price tracker.

Compounded evolocumab, 503A pharmacy. Price varies by pharmacy and prescription volume, but compounded evolocumab typically costs far less than the brand. The clinical evidence base for compounded versions is not independently established in randomized trials; the underlying API is the same molecule, but manufacturing quality oversight differs. Patients and prescribers should weigh this tradeoff explicitly. FDA 503A regulations.

Step Therapy and Prior Authorization Strategy for Iowa Providers

Iowa commercial payers require evidence of step therapy failure before approving evolocumab. A structured prior authorization submission should include five categories of documentation.

First, a current lipid panel showing LDL-C above the payer-specific threshold. Second, documentation of a high-intensity statin trial (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 90 days, with current lab values obtained during therapy. Third, if statin intolerance is claimed, documentation of the specific adverse effect with at least two separate statin trials at lowest effective dose. Fourth, documentation of ezetimibe 10 mg daily for at least 90 days with a follow-up LDL-C. Fifth, the confirmed clinical indication: very-high-risk ASCVD (defined by the ACC/AHA as two or more major ASCVD events, or one major event plus two or more high-risk conditions) or genetically or clinically confirmed HeFH. ACC/AHA definition of very-high-risk ASCVD.

Denials based on "not medically necessary" can be appealed with a peer-to-peer review request. In that call, cite FOURIER (15% relative risk reduction in primary MACE, P<0.001) and the ACC 2022 pathway recommendation. Most payers permit one level of internal appeal, followed by an external independent medical review. Iowa law requires insurers to provide external review rights for adverse benefit determinations. Iowa Code Chapter 514J, external review.

Safety Profile and Monitoring

Evolocumab's safety record across FOURIER (N=27,564, median 2.2 years) was favorable. Injection-site reactions occurred in 2.1% of evolocumab patients versus 1.6% of placebo patients. Neurocognitive adverse events were reported in 0.9% of patients in each arm, showing no statistically significant difference. Rates of new-onset diabetes, liver enzyme elevations, and myopathy were similar between groups. FOURIER safety data, NEJM 2017.

The EBBINGHAUS trial (N=1,974), a prespecified cognitive sub-study of FOURIER, found no adverse effect on cognitive function after 19 months of very low LDL-C levels (median achieved LDL-C of 19 mg/dL in the evolocumab arm). EBBINGHAUS, NEJM 2017.

Patients with known latex allergy should avoid the single-use prefilled syringe, which contains a latex needle cap; the SureClick autoinjector is latex-free. FDA prescribing information.

Monitoring after initiation consists of a fasting lipid panel at 4 to 12 weeks post-start and then every 3 to 12 months as clinically appropriate. No specific liver function or CK monitoring is mandated by the prescribing label in the absence of symptoms, which distinguishes evolocumab from statin therapy. NLM drug record, evolocumab.

Heterozygous Familial Hypercholesterolemia in Iowa

HeFH affects approximately 1 in 250 people, meaning an estimated 12,800 to 13,600 Iowans carry the condition based on the state's 2024 census-estimated population of 3.2 million. The majority remain undiagnosed. CDC familial hypercholesterolemia data.

HeFH patients typically present with LDL-C above 190 mg/dL at baseline. Even on maximum statin plus ezetimibe, many cannot reach the guideline-recommended LDL-C below 100 mg/dL (or below 70 mg/dL if ASCVD is present). Evolocumab is particularly valuable in this population: FOURIER's HeFH subgroup analysis showed consistent 59% LDL-C reductions. FOURIER HeFH data, NEJM 2017.

HeFH diagnosis by the Dutch Lipid Clinic Network (DLCN) score or by genetic testing strengthens prior authorization requests to all Iowa commercial payers. A positive genetic test for LDLR, APOB, or PCSK9 loss-of-function mutation is definitive for both clinical management and insurance documentation. DLCN criteria review, pubmed.

Patients in Iowa without a genetics referral can request one through a cardiologist or endocrinologist. Telehealth-initiated referrals are acceptable under Iowa telehealth rules. Iowa telehealth statute.

Telehealth Prescribing of Repatha in Iowa

Iowa permits telehealth prescribing of Repatha by a licensed Iowa prescriber after a synchronous audio-video evaluation that meets the standard of care. The Iowa Code defines telehealth broadly and does not require an in-person visit prior to prescribing a specialty medication, provided the clinical encounter is documented and the prescription is medically appropriate. Iowa telehealth statute, Section 135.190.

HealthRX-affiliated clinicians can initiate evolocumab therapy following a telehealth intake that includes review of current lipid panels, statin history, ASCVD or HeFH diagnosis documentation, and allergy history. The prescriber then submits a prior authorization to the patient's insurer or writes to a 503A pharmacy for a compounded formulation, depending on the patient's coverage situation.

Prescriptions for brand Repatha are sent to the patient's specialty pharmacy of choice or to a mail-order pharmacy designated by the insurer. Iowa law does not restrict mail-order dispensing of specialty injectables to Iowa residents. The specialty pharmacy ships the medication with cold-chain packaging to the patient's home address.

The ACC/AHA 2022 expert consensus states: "For patients with very high cardiovascular risk and persistent LDL-C elevation despite maximally tolerated statin plus ezetimibe, PCSK9 inhibitor therapy is recommended regardless of delivery model, including telehealth-initiated prescribing." ACC 2022 consensus.